In our prospective analysis on HER2-negative breast cancer patients treated with mBev beyond controlled disease after first-line BT therapy, the ORr (CR + PR, 62.8%) resembled those reported in large randomized phase III trials[7-9]. The gene discussed is ERBB2; the disease is breast carcinoma.